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Purpose   the aim of the present study was to investigate the efficacy of artemether-
lumfantrine (Co-Artesiane®) suspension for the treatment of uncomplicated Plasmodium 
falciparum malaria in children (aged 6-59 months) in Kassala in eastern Sudan. 
Method This was a prospective clinical trial where the artemether-lumfantrine (Co-Artesiane®) 
suspension was given for three days and the patients were followed-up for 28 days 
Results:   Forty-eight patients were enrolled in the study and 43 of them completed the 28-
days follow-up. Treatment rapidly cleared parasitemia and fever. The overall 28-day cure rate 
was 100% and no clinical or parasitological failures were observed among these patients.  
Mild side effects were observed in three (7%) children.   
Conclusion: Artemether-lumfantrine (coartem) suspension appears to be efficacious and safe 
for the treatment of uncomplicated malaria. 
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INTRODUCTION 
There are almost one million childhood deaths in 
Africa due to P. falciparum infections every year 
1. Children are at higher risk for developing drug-
resistant falciparum malaria than older 
individuals 2. Countries with high levels of 
resistance have witnessed increased childhood 
morbidity and mortality 3. 
 Malaria causes around 7.5 – 10 million clinical 
cases and 35,000 deaths every year in Sudan 4. 
High levels of chloroquine and 
sulphadoxine/pyrimethamine resistance were 
reported among Sudanese children 5-6. Due to 
the spread of multidrug-resistant Plasmodium 
falciparum malaria in Sudan 7, artesunate plus 
sulfadoxine–pyrimethamine (AS+SP) is 
recommended as the first-line drug while 
artemehter-lumefantrine (AT-LU, Coartem®) is 
the second line drug in the treatment of 
uncomplicated P. falciparum malaria. The 
assessment and monitoring of antimalarial 
therapeutic efficacy is key to the provision of 
sound evidence for policy decisions making, 
regarding which antimalarials can be adopted for 
malaria case management. The choice of an 
artemisinin-combinations therapy (ACTs) in 
specific malaria-endemic areas needs to take 
into account their efficacy, tolerability, cost and 
ease of administration. Most therapies with 
ACTs last for 3 days and in some instances the 
patient has to swallow up to 24 tablets. 
However, this mode of administration may be 
unsuitable for infants and young children. It is, 
therefore, imperative that a simpler mode of 
administration is developed. Such a dosage 
form should be stable under tropical conditions 
8. The preliminary reports on an AT-LU 
suspension (Co-artesiane®) developed by Dafra 
Pharma NV. The objective of this trial, therefore, 
was to investigate the efficacy of this drug (Co-
Artesiane® suspension) in the treatment of 
uncomplicated P. falciparum malaria in under 
five children in a health centre in Sudan.  
MATERIAL AND METHODS  
Study area 
  The study was conducted at the health center 
in Kassala area in eastern Sudan during the 
period September-November 2005. Kassala is 
an agricultural area, located 500 Km from 
Khartoum. It is characterized by unstable 
malaria transmission with the peak during the 
rainy and post-rainy season 9. The predominant 
malaria species is P. falciparum, and Anopheles 
arabiensis is the sole malaria vector in the area 
10. The study received ethical clearance from the 
Ethical Board of The Academy of Medical 
Sciences and Technology. 
Patients 
  Children (6-59 months of age) with 
documented axillary temperature ≥ 37.5 0C and 
P. falciparum infection were eligible for inclusion 
if their parents gave informed consent. Children 
were excluded if they had one or more of 
manifestations of severe malaria 11/ concurrent 
infection. 
  All the enrolled children underwent a thorough 
history and physical examination conducted by a 
medical officer and thereafter received AT-LU 
(Co-Artesiane®) suspension according to the 
manufacturers` (Dafra Pharma NV) instructions. 
The dry powder was advised to be dissolved in 
water to prepare 60 ml of the drug, containing 
180 mg of artemether and 1080 mg of 
lumefantrine. The dose was calculated 
according to body weight; 4mg artemether/kg for 
three days. However, an approximation was 
used and the following dosage regimens were 
administered: 7ml for children weighing less 
than 5kg, 10ml  for those weighing >5 – 7.5kg, 
14ml for >7.5 – 10kg and 20ml for children 
weighing 10kg and higher. 
 The children were given the medication orally 
under supervision and were monitored for 30 
minutes. A second full dose was administered if 
the child vomited the first dose within this 
monitoring period. Children who vomited the 
drug for a second time were excluded from the 
study and were given parental quinine.   
 
Investigations 
 Finger prints blood films were prepared, Giemsa-
stained and examined by 100x magnification of an 
oil immersion field. The parasite density was 
counted against 200 leucocytes, assuming 8000 
leucocytes/µl. All slides were double-checked 
blindly and only considered negative if no 
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parasites were detected in 100 oil immersion 
fields. If gametocytes were seen, then the count 
was extended to 500 leucocytes.  
 
Follow-up 
  Parents were asked to bring their children for 
follow-up on days 1, 2, 3, 7, 14, 21 and 28 or if 
they developed febrile symptoms and felt unwell. 
At each visit, parents were asked about the 
presence of fever, vomiting and diarrhea. In 
addition, brief physical examination, including 
axillary temperature was performed and the 
blood was taken for thick films.  
Outcome measures 
Early Treatment Failures (ETF) in case of 
significant parasitaemia at day 2 or 3 or 
parasites and fever at day 3, Late Clinical 
Failures (LCF) for cases with parasites and fever 
during follow-up after day 3 and Late 
Parasitological Failures (LPF) for parasite 
infections with/without fever during the follow-up 
period. Cases which remained negative during 
follow-up were considered to be Adequate 
Clinical and Parasitological Responses (ACPR). 
These were modified from WHO guidelines 12- 13. 
 
RESULTS 
  Forty-three patients (77.5%) out of 48 have 
completed the 28–day study period. The others 
were excluded because to loss of follow-up due 
to change of their addresses.  
The presenting mean (SD) of the age was 3.7 
(1.2) years and the body weight range was 6 - 
23 kg with mean (SD) of 13.9(3.5) kg. The mean 
(SD) of the temperature and the parasite count 
were 38.5 (0.6) 0C and 7915.4(5869.0) rings /µl 
respectively. Fourteen (31.8%) out of the 43 
patients were female. On day 1, 15 (34.1%) 
patients were still febrile and 11(25%) were still 
parasitaemic. On day 3, fever was not detected 
in any of the patients and all patients were 
aparasitaemic. Mild side effects (nausea and 
diarrhea) were reported among three (7%) 
children; however, these were mild and resolved 
spontaneously. Gametocytes were detected in 
four (9.1%) patients on enrollment and it was 
detected in one patient (2%) during the follow-up 
period (day 21). 
DISCUSSION 
This is probably the first publication on the AT-
LU suspension in the treatment of 
uncomplicated falciparum malaria in children 
below five years of age. The study was 
conducted in an area characterized by high 
(antimalarial) drug resistance 14- 15. 
The study showed a full efficacy (100%) of the 
AT-LU suspension for the treatment of 
uncomplicated falciparum malaria in this area, 
and no cases of treatment failure detected 
during the 28-day follow-up period. Recently, a 
full efficacy of the AT-LU tablets was reported in 
an area of unstable malaria transmission in 
central Sudan 16. In an earlier study, AT-LU 
tablets had shown 93.9% and 97.5% efficacy in 
African children with uncomplicated falciparum 
malaria 17-18. In a neighboring country, Ethiopia, 
99% efficacy was reported for the AT-LU tablets 
for the treatment of children with uncomplicated 
falciparum malaria. Caution should be taken 
when comparing with the former study, because 
children weighing less than 10 kg were excluded 
19.  
Previously AT-LU is available in the form of 
tablets and the patients had to swallow up to 24 
tablets and the idea of this simple form 
(suspension) was emerged to enhance the 
compliance. Recently, the bioavailability of 
chloroquine suspension was comparable with 
that of chloroquine syrup as standard 20. Yet, 
due to the spread of chloroquine resistance, the 
chloroquine suspension might not be the 
preferred choice. The preliminary data on 
artemisinins suggested artemether as an 
optimum candidate 8  and the combination was 
emerged. 
Due to the age factor, it was difficult to monitor 
or detect the adverse effects in the studied 
children. However, nausea and mild diarrhea 
were reported in three patients. One of the 
limitations of this study was the lack of 
electrocardiographic monitering. It had been 
reported that, AT-LU in the treatment of 
uncomplicated falciparum malaria was free from 
any electrocardiographic evidence of 
cardiotoxicity 17-18. 
There was one case of gametocytaemia during 
the follow-up period.  The ability of artesunate to 
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reduce the post-treatment gametocytaemia is 




artesiane®) appears to be efficacious and safe 
for the treatment of uncomplicated malaria. 
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